The D:A:D study did not find a significantly increased risk of cardiovascular events with ATV [ 29 , 41 ], and the Centers for AIDS Research Network of Integrated Clinical Systems cohort found a nonsignificant trend toward a reduced risk of atherosclerotic events with ATV compared with other protease inhibitors (hazard ratio 0.78; 95% CI: 0.42–1.45) [ 52 ].
← all excerpts
Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
1
—
—